Displaying drugs 801 - 825 of 1291 in total
Nomacopan
Nomacopan is under investigation in clinical trial NCT03427060 (Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms).
Investigational
Matched Categories: … Recombinant Protein Inhibitor of Complement Factor 5 …
Temocapril
Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in the United States, but is approved in Japan and South Korea. Temocapril can also be used in hemodialysis patients without risk of serious accumulation.
Experimental
Investigational
Matched Description: … Temocapril is a prodrug-type angiotensin-I converting enzyme (ACE) inhibitor not approved for use in …
Icotinib
Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)
Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc. was given a “May Proceed” from the US FDA to conduct a Phase I study for the...
Experimental
Investigational
Matched Description: … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ( …
Imalumab
Imalumab is under investigation in clinical trial NCT02540356 (Phase 1/2a Two-arm Dose-escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer).
Investigational
Elinogrel
A P2Y12 inhibitor and platelet aggregation inhibitor.
Investigational
Matched Description: … A P2Y12 inhibitor and platelet aggregation inhibitor. …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor …
Sacubitrilat
A metabolite of LCZ696 with neprilysin inhibitory activity.
Experimental
Matched Categories: … Neprilysin Inhibitor …
Iproniazid
Withdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Withdrawn
OSI-7904L
OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced gastric and/or gastroesophageal adenocarcinoma (A-G/GEJA). Current treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.
Investigational
Matched Description: … OSI-7904L is a liposome encapsulated thymidylate synthase inhibitor, which is indicated for use in advanced ... innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor …
Amuvatinib
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA...
Investigational
Matched Description: … Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET …
Batimastat
Experimental
Fimasartan
Fimasartan is an angiotensin II receptor antagonist (ARB) drug employed in the treatment of both hypertension and heart failure. It has been found to be safe when administered with hydrochlorothiazide (a diuretic) in clinical trials. Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the...
Investigational
Tenofovir
Tenofovir is an acyclic nucleotide diester analog of adenosine monophosphate. In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. The antiviral activities of tenofovir were first reported in 1993 and...
Experimental
Investigational
Matched Categories: … Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor ... Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor …
2-deoxyglucose
2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel). By using positron emission tomography (PET), radiolabelled 2-deoxyglucose can determine glucose metabolism, which is altered in diseases such as cardiovascular disease, tumors, and Alzheimer's disease. Therapeutically, 2-deoxyglucose is an investigational drug that...
Experimental
Investigational
Matched Description: … still being investigated, but it is known that in hypoxic cancer cells, 2-deoxyglucose is a glycolysis inhibitor …
Thenoyltrifluoroacetone
Thenoyltrifluoroacetone is a chelating agent and inhibitor of cellular respiration.
Experimental
Matched Description: … Thenoyltrifluoroacetone is a chelating agent and inhibitor of cellular respiration. …
Emprumapimod
Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor. It was investigated for dilated cardiomyopathy.
Investigational
Matched Description: … Emprumapimod is a potent, orally active and selective inhibitor of p38α mitogen-activated kinase inhibitor …
Omapatrilat
Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). The inhibition of NEP elevates natriuretic peptide levels, increasing excretion of sodium in urine, dilating blood vessels, and reducing preload and ventricular remodeling. This drug from BMS was not approved by the FDA due...
Investigational
Itacitinib
Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others.
Investigational
Matched Categories: … Janus Kinase Inhibitor …
AZD3409
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Investigational
Matched Description: … AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. …
Marimastat
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Investigational
Matched Description: … As an angiogenesis inhibitor it limits the growth and production of blood vessels. ... Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. …
Banoxantrone
Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of tumours compared to administration of either banoxantrone or radiation alone. Banoxantrone was also efficacious in...
Investigational
Cambritaxestat
Cambritaxestat is an autotaxin inhibitor.
Investigational
Matched Description: … Cambritaxestat is an autotaxin inhibitor. …
Ubenimex
Ubenimex (also known as bestatin) is a competitive protease inhibitor. It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. It is being studied for use in the treatment of acute myelocytic leukemia.
Investigational
Matched Description: … Ubenimex (also known as bestatin) is a competitive protease inhibitor. ... It is an inhibitor of aminopeptidase B, leukotriene A4 hydrolase, aminopeptidase N. …
Displaying drugs 801 - 825 of 1291 in total